EBV P23 (DAG2373)

EBV P23 (aa 1 - 162), recombinant protein from E. coli

Product Overview
The E.Coli derived recombinant protein contains the HHV-4 p23 regions, 1-162 amino acids.
> 95%, based on SDS PAGE
Each vial contains 100 μg of lyophilized protein in 25mM glycine pH-9.6 and 50% glycerol.
2-8°C short term, -20°C long term
The Epstein-Barr virus (EBV), also called Human herpes virus 4 (HHV-4), is a virus of the herpes family (which includes Herpes simplex virus and Cytomegalovirus. On infecting the B-lymphocyte, the linear virus genome circularizes and the virus subsequently persists within the cell as an episome. The virus can execute several distinct programs of gene expression which can be broadly categorized as being lytic cycle or latent cycle. The lytic cycle or productive infection results in staged expression of a host of viral proteins with the ultimate objective of producing infectious virions. Formally, this phase of infection does not inevitably lead to lysis of the host cell as EBV virions are produced by budding from the infected cell. The latent cycle (lysogenic) programs are those that do not result in production of virions. A very limited, distinct set of viral proteins are produced during latent cycle infection. These include Epstein-Barr nuclear antigen (EBNA)-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, EBNA-leader protein (EBNA-LP) and latent membrane proteins (LMP)-1, LMP-2A and LMP-2B and the Epstein-Barr encoded RNAs (EBERs).
Antigen Description
The Epstein Barr virus (EBV) is a human herpes virus 4 (HHV4) that infects and establishes latency in B-lymphocytes. Primary infection leads to a life-long past infection which is normally asymptomatic. EBV expresses a number of genes, however, Epstein Barr nuclear antigen 1 (EBNA1) p72 is the only viral protein which characterizes EBV past-infection. p23 is one of the two small viral capsid antigens (VCA). EBV p23 is a viral late complex associated with virion particles and consists of two gene products, BFRF3 and BLRF2. EBV has a worldwide distribution, with over 90% of the adult population showing evidence of past infection. The virus, acquired during childhood, usually causes no symptoms. However, in Western societies, 10 to 20% of adolescents and young adults develop acute infectious mononucleosis (IM). In humans, EBV is also associated with cancer, in particular Burkitt's lymphoma, nasopharyngeal carcinoma, Hodgkin's disease, and immunoblastic lymphoma.
Epstein–Barr virus; Herpesviridae; Gammaherpesvirinae; Lymphocryptovirus; Human herpesvirus 4; HHV-4; EBV; p18 protein


Have you cited DAG2373 in a publication? Let us know and earn a reward for your research.

Related Products

EBV P23 [GST] (DAG511)
EBV P23 (DAG3928)

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Efficient evaluation of humoral immune responses by the use of serum pools


Authors: Sternbaek, Louise; Draborg, Anette H.; Nielsen, Christoffer T.; Jacobsen, Soren; Iversen, Line V.; Troelsen, Lone; Theander, Elke; Houen, Gunnar

Background: Collection and testing of individual serum samples are often used in research to gain knowledge about e.g. the humoral response against bacteria or virus. This is a valid but time-consuming method and might be a waste of valuable serum samples for inefficient research. So far, no study has considered using serum pools as a quick and efficient screening method to confirm or deny hypotheses. Methods: We created serum pools from four different patient groups (systemic lupus erythematosus n = 85, rheumatoid arthritis n = 77, Sjogren's syndrome n = 91, systemic sclerosis n = 66) and one healthy control group (n = 67). Each serum pool was analyzed using three well-known immunoassays: enzyme-linked immunosorbent assay (ELISA), line blot, and immunofluorescence microscopy (anti-nuclear antibody (ANA) screening). The presence of Epstein -Barr virus (EBV) EA/D-, EBNA-1-, VCA p23-, and gp350-directed antibodies was used to validate serum pools as an efficient tool for further investigations by comparison to previous findings in this area. Results: The presence of EBV EA/D-, EBNA-1-, VCA p23-, and gp350-directed antibodies in each pool was consistent within the obtained ELISA and line blot results, as increased titers of IgG against the four antigens were found in all patient serum pools and also in individual sera regarding gp350. These results correspond to previous findings on individual samples from patients with these diseases. The presence of ANAs was observed in all four patient serum pools and not in the HC pool by both line blots and immunofluorescence microscopy, which corresponds with the expectations and further corroborate the application of serum pools for screenings. Conclusion: We developed and validated the use of serum pools that reliably and rapidly can confirm or deny hypotheses, which enables a more efficient research concentrating on the most evident factors. (C) 2017 Elsevier B.V. All rights reserved.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket